Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies

Hematological Oncology

Volumn 18, Issue 4, 2000, Pages 141-153

  Johnson, S A ^a   Thomas, W ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Cladribine; Combination therapy; Fludarabine; Lymphoma; Lymphoproliferative disease

Indexed keywords

ADENOSINE DEAMINASE; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTHRAQUINONE; CD20 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE KINASE; DEOXYRIBONUCLEOTIDE; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; FLUDARABINE; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PLACEBO; PLATINUM; PREDNISOLONE; PREDNISONE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; REVIEW;

EID: 0034492511     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1069(200012)18:4<141::aid-hon666>3.0.co;2-%23     Document Type: Review

References (63)

1. Termination of DNA synthesis by 9-β-D-arabinosyl-2-fluoroadenine: A mechanism for cytotoxicity
2. Mechanism of deoxyadenosine 2′-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes
3. The biochemical and clinical consequences of 2′ deoxycoformycin in refractory lymphoid malignancy
4. Induction of apoptotic cell death in chronic lymphocytic leukaemia by 2 chloro-2′-deoxyadenosine and 9-βD-arabinosyl-2-fluoroadenine
5. Differential incorporation of araC, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukemia cells
6. Functional compartmentation of dCTP pools: Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts
7. Corticosteroid therapy for lymphomas chronic lymphocytic leukemia
8. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic and molecular analysis
9. Fludarabine and prednisone in pre-treated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages
10. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multi-variate analysis-derived prognostic model for response to treatment
11. Cladribine with or without prednisone in the treatment of previously treated untreated B-cell chronic lymphocytic leukaemia - Updated results of the multicentre study of 378 patients
12. Phase II trial of fludarabine phosphate interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome
13. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A South West Oncology Group Study
14. Phase I trial of fludarabine monophosphate (FAMP) plus alpha interferon (IFN-A) in refractory low-grade Non-Hodgkin's Lymphoma (NHL)
15. Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal
16. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia
17. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A South West Oncology Group Study
18. Fludarabine induces a high-complete remission rate in previously untreated patients with active chronic lymphocytic leukemia. A randomized Inter-Group study
19. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma
20. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results long-term follow-up - A report from the Eastern Co-Operative Oncology Group
21. Fludarabine and cyclophosphamide as first therapy for indolent lymphoproliferative disorders: Response rates toxicity
22. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies
23. Combined therapy with fludarabine and cydophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia non-Hodgkin's lymphomas
24. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas
25. Combination therapy with fludarabine cyclophosphamide as salvage treatment in lymphoproliferative disorders
26. Fludarabine ,cyclophosphamide and dexamethasone (FluCyD) combination is effective in pre-treated low-grade non-Hodgkin's lymphoma
27. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia
28. Sequential administration of fludarabine, araC and mitoxantrone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia
29. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
30. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia
31. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German Multicenter phase II study
32. A new effective treatment for indolent lymphoma: A pilot study with fludarabine, idarubicin and prednisone combination (FLIDA)
33. FLU-Id (fludarabine and idarubicin) regimen as salvage therapy in pre-treated low-grade non-Hodgkin's lymphoma
34. Randomized trial of fludarabine versus fludarabine idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
35. Phase I study of the combination of fludarabine, mitoxantrone and dexamethasone in low-grade lymphoma
36. Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma
37. Fludarabine-mitoxantrone combination containing regimen in recurrent low-grade non-Hodgkin's lymphoma
38. A phase II study to evaluate the combination of fludarabine mitoxantrone, dexamethasone (FMD) in patients with follicular lymphoma
39. Stage IV low grade lymphoma (LGL): Randomized trial of two innovative regimens, with monitoring of BCL-2 by PCR
40. Cladribine mitoxantrone dose-escalation in indolent non-Hodgkin's lymphoma
41. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low-grade non-Hodgkin's lymphoma
42. Fludarabine and mitoxantrone: A highly effective and well-tolerated salvage therapy for low-grade lymphoproliferative disorders
43. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial
44. Fludarabine and mitoxantrone therapy in chronic lymphocytic leukemia
45. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas
46. Fludarabine, cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia and follicular lymphoma
47. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells
48. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia
49. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
50. High-dose cytosine arabinoside in chronic lymphocytic leukemia: A clinical and pharmacologic analysis
51. Combination of fludarabine and arabinosyl cytosine for treatment of chronic lymphocytic leukemia: Clinical efficacy and modulation of arabinosyl cytosine pharmacology
52. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair
53. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance
54. Cisplatin, fludarabine and araC (CFA): A regimen for advanced fludarabine refractory chronic lymphocytic leukemia
55. Sequential cis-platinum, fludarabine and arabinosyl cytosine (PFA) or cyclophosphamide, fludarabine and arabinosyl cytosine (CFA) in patients with Richter's Syndrome: A pilot study
56. Fludarabine, cisplatin and araC in patients with anthracycline-refractory intermediate-grade and high grade non-Hodgkin's lymphoma: The International Oncology Study Group (IOSG) NHL 2 Study
57. FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma
58. Fludarabine and cyclophosphamide combined with Rituxan (FCR) is a potent cytoreductive regimen as initial therapy of chronic lymphocytic leukemia
59. 131I Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma
60. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
61. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
62. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
63. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukemia and lymphoma